Afatinib with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutation:phaseI study
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2016 Status changed from not yet recruiting to recruiting.
- 20 Dec 2014 New trial record